GlaxoSmithKline Pharmaceuticals Limited Cash Flow-to-Debt Ratio
GlaxoSmithKline Pharmaceuticals Limited cash flow-to-debt ratio. GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2023, meaning its operating cash flow of Rs362.20 Million could theoretically repay 0% of its total liabilities (Rs17.31 Billion) in one year. Check GlaxoSmithKline Pharmaceuticals Limited earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GlaxoSmithKline Pharmaceuticals Limited (2005–2025)
Cash flow-to-debt ratio of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025. Historical debt coverage capacity for GlaxoSmithKline Pharmaceuticals Limited across 21 annual periods. Check GLAXO capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
GlaxoSmithKline Pharmaceuticals Limited Cash Flow-to-Debt Ratio by Year (2005–2025)
GlaxoSmithKline Pharmaceuticals Limited cash flow-to-debt ratio by year from 2005 to 2025. Year-by-year debt coverage analysis for GlaxoSmithKline Pharmaceuticals Limited. For the full cash flow conversion analysis, see GLAXO operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.60x | Rs12.90 Billion | Rs21.57 Billion | ▲ +82.8% |
| 2024 | 0.33x | Rs5.82 Billion | Rs17.79 Billion | ▲ +7.1% |
| 2023 | 0.31x | Rs4.84 Billion | Rs15.85 Billion | ▼ -25.8% |
| 2022 | 0.41x | Rs8.11 Billion | Rs19.70 Billion | ▲ +14.9% |
| 2021 | 0.36x | Rs5.78 Billion | Rs16.14 Billion | ▼ -4.0% |
| 2020 | 0.37x | Rs4.90 Billion | Rs13.15 Billion | ▲ +65.5% |
| 2019 | 0.23x | Rs3.99 Billion | Rs17.71 Billion | ▼ -9.9% |
| 2018 | 0.25x | Rs4.73 Billion | Rs18.90 Billion | ▲ +5.7% |
| 2017 | 0.24x | Rs2.36 Billion | Rs9.97 Billion | ▲ +129.6% |
| 2016 | 0.10x | Rs1.39 Billion | Rs13.50 Billion | ▼ -70.2% |
| 2015 | 0.35x | Rs2.70 Billion | Rs7.80 Billion | ▲ +40.2% |
| 2014 | 0.25x | Rs2.81 Billion | Rs11.40 Billion | ▼ -14.9% |
| 2013 | 0.29x | Rs3.14 Billion | Rs10.82 Billion | ▼ -2.4% |
| 2012 | 0.30x | Rs3.36 Billion | Rs11.30 Billion | ▼ -46.8% |
| 2011 | 0.56x | Rs4.79 Billion | Rs8.59 Billion | ▼ -22.3% |
| 2010 | 0.72x | Rs5.12 Billion | Rs7.12 Billion | ▲ +62.2% |
| 2009 | 0.44x | Rs3.30 Billion | Rs7.45 Billion | ▼ -9.0% |
| 2008 | 0.49x | Rs3.19 Billion | Rs6.55 Billion | ▲ +10.0% |
| 2007 | 0.44x | Rs2.59 Billion | Rs5.84 Billion | ▼ -28.7% |
| 2006 | 0.62x | Rs3.49 Billion | Rs5.63 Billion | ▲ +32.9% |
| 2005 | 0.47x | Rs2.29 Billion | Rs4.90 Billion | — |